HIVEVO

Intra-patient evolution of HIV

Coordinatore	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Germany [DE]
Totale costo	1˙155˙859 €
EC contributo	1˙155˙859 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2010-StG_20091118
Funding Scheme	ERC-SG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-03-01   -   2016-02-29

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Ms. Nome: Evelyn Cognome: Göransson Email: send email Telefono: +46 8 524 879 64	SE (STOCKHOLM)	beneficiary	187˙200.00
2	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Dr. Nome: Richard Cognome: Neher Email: send email Telefono: +49 7071 6011345 Fax: +49 7071 6011308	DE (MUENCHEN)	hostInstitution	968˙659.00
3	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Mr. Nome: Patrice Cognome: Wegener Email: send email Telefono: +49 7071 6011791 Fax: +49 7071 6011793	DE (MUENCHEN)	hostInstitution	968˙659.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'HIV is one of the most rapidly evolving organisms known. Understanding its evolutionary dynamics is essential for successful drug treatment or vaccine design. At the same time, this rapid evolution makes HIV an ideal model system to study fundamental problems in evolutionary dynamics: In HIV, one can directly observe evolution over genetic distances that correspond to millions of years of evolution in other organisms. This proposal combines time series of ultra-deep sequence data of HIV from individual patients, functional information on drug resistance, and methods from statistical physics to study evolution. The sequence data will observe the dynamics of the genotype distribution in the population, while the exceptionally well characterized biology of HIV will allow the assignment of functional significance to the observed genotypic changes. These two levels of description will be integrated by theoretical models that describe how selection on phenotypes feeds back on the genotype distribution. Specifically, we will determine the fundamental parameters of HIV evolution such as selection strength, recombination rates, and the patterns of genetic interactions from the time resolved data obtained by deep sequencing. We will use the data base of viral sequences that evolved in response to drug treatment to infer the fitness landscapes of drug resistance. These two projects will be integrated in a quantitative model of drug resistance evolution. In a third project, we will quantify how genetic interactions affect the formation of circulant recombinant forms of HIV. Using HIV as a model system, we will develop and test theories of multi-locus evolution, characterize fitness landscapes and genetic interactions, and quantify the impact of recombination on HIV evolution.'